Home » Clinical Trials » Inherited retinal dystrophy » NCT01482195
NCT01482195

Phase I Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-VMD2-hMERTK) Gene Vector to Patients With Retinal Disease Due to MERTK Mutations

Study Summary

This study was to assess the safety of gene transfer via subretinal administration of rAAV2-VMD2-hMERTK in subjects with MERTK-associated retinitis pigmentosa (RP).

Want to learn more about this trial?

Request More Info

Interventions

Subretinal administration of rAAV2-VMD2-hMERTKRecombinant Adeno-Associated VirusBIOLOGICAL
The study is an open-label, dose-escalation, phase I clinical trial of subretinal administration of rAAV2-VMD2-hMERTK in patients with retinitis pigmentosa due to MERTK mutation.

Study Locations

FacilityCityStateCountry
King Khaled Eye Specialist HospitalRiyadhSaudi Arabia

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026